Which of the following best describes the main data-privacy considerations in a clinical trial?

• A. Sharing data widely to accelerate research.
• B. Only de-identification; nothing about access or laws.
• C. Keeping data in local sites without restrictions.
• D. Protecting confidentiality, controlled access, de-identification, and compliance with privacy laws.

Answer: (D)

Data privacy in a clinical trial centers on protecting participant confidentiality throughout the study, by restricting access to authorized personnel, applying de-identification where possible, and complying with privacy laws. The best option reflects all of these elements: it emphasizes keeping data confidential, ensuring access is controlled, using de-identification to reduce identifiability when data are shared, and following applicable privacy regulations. This combination supports participant protection, ethical oversight, and legal compliance while still enabling the responsible use of data for research. In contrast, simply de-identifying data without addressing who can access it or the legal requirements, or advocating unrestricted sharing or unrestricted local storage, would leave privacy risks and regulatory gaps unaddressed.